Is TB-500 Legal in Minnesota? Federal Law, State Rules, and How to Get It
HealthRX.com
TB-500 has no approved legal route in Minnesota yet
See the public record for TB-500
At a glance
- FDA approval / None; no approved drug contains TB-500 [1]
- FDA compounding lists / In none of the three categories on FDA's pharmacy bulk-substance list and absent from the outsourcing-facility list; the category 1 policy does not cover it [2][3][6]
- FDA safety-risk page / In the nominated but withdrawn table, not the active category 2 table [7]
- July 2026 advisory vote / Committee favored adding it; advice only, not binding [8][4]
- HHS October 2026 policy / Draft enforcement discretion for TB-500 acetate by injection; not final [4][5]
- Human studies / None found in which TB-500 was given to a person [1]
- Sport / Prohibited at all times by WADA [9]
Why TB-500 is not simply legal
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, and no FDA-approved drug contains it. FDA found no USP or National Formulary monograph for it [1]. Under federal compounding rules, a state-licensed pharmacy may use a bulk substance only if an applicable USP or National Formulary monograph exists, the substance is a component of an FDA-approved drug, or it appears on FDA's bulk-substance list for those pharmacies [6]. TB-500 meets none of those conditions [1][2][6].
It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026). It is likewise absent from FDA's list for outsourcing facilities (updated March 21, 2025), and the category 1 policy does not cover it [2][3][6]. FDA lists it in the nominated but withdrawn table of its safety-risk page rather than the active category 2 table, and removal from category 2 was not a finding of safety [7]. FDA's stated concerns are missing human exposure data, missing safety information, and immunogenicity risk from aggregation and peptide-related impurities in injectable peptides [7].
What people on Reddit report
Reddit comments from a discussion of a recent FDA committee vote. The accounts range from a pharmacy owner describing state board guidance to patients asking whether their clinic's setup is legal.
Speaking to my state board, they said providers can prescribe any peptide therapy they want as off label use, but the pharmacies are not allowed to compound them.Read the source discussion
I go to a wellness clinic that specializes in peptides and the doctor actually prescribes them to be compounded in a verified 503a Pharmacy. I thought that as of right now, there was kind of a grey area in the system that allows for pharmacies and doctors to do that and it's not actually illegal.Read the source discussion
I'm super excited. Like you said, it's an advisory committee vote so the fda might just slap it down, but it's a step in the right direction.Read the source discussion
Questions worth asking
The July 2026 advisory vote
FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026 and voted in favor of adding it to the bulks list, against FDA staff's recommendation. The vote is advice only, TB-500 is not on the list, and adding it takes formal rulemaking [8][4]. FDA staff had proposed that neither the free base nor the acetate be added. They cited inconsistent naming, no impurity, aggregate or endotoxin data, no human data of any kind, and immunogenicity risk [1].
Dr Ashley Froese on why the FDA vote may not fix the gray market
Dr. Ashley Froese argues that the upcoming FDA advisory committee meeting will not fix the gray market for peptides. She says the review asks whether the evidence supports specific medical uses, not whether the peptides work, and that doctors can still prescribe an approved ingredient off-label. On thymosin beta four, she describes it as a cell-building protein that guides cells to an injury site, which is why people use it for wound healing and joint pain. She is skeptical that a vote will stop research peptide websites or telehealth startups, saying the horse has already left the barn. She closes by asking viewers what they think.
Who is speaking?
Dr. Ashley Froese. Doctor and YouTube host, as described on the channel Background
The October 2026 HHS draft
HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192, publication scheduled October 30, 2026). It names TB-500 among six peptides and covers TB-500 acetate by subcutaneous or intramuscular injection [4][5]. Its conditions include a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [5]. The notice says it establishes no rights for any person, is not binding on HHS or the public, and may be revisited [4]. It does not put TB-500 on any list [4].
Availability and sport
These federal rules apply to pharmacies and physicians in Minnesota as in other states. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times in and out of competition. It is on the 2026 List and stays on the 2027 List [9][10].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is TB-500 legal in Minnesota?
Can a pharmacy compound TB-500 now?
Did the advisory committee vote make TB-500 compoundable?
Has TB-500 been tested in people?
Is TB-500 banned in sport?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Reddit participants. The FDA committee just voted yes on BPC, TB-500, and 4 others. (r/NTNPerformance). Accessed 2026-11-11.
- This Is Not Covered - Dr. Ashley Froese. The FDA Is About to Decide the Future of Peptides: BPC-157, TB-500, KPV, & MOTS-C. Accessed 2026-11-11.